Monoclonal antibody · Antagonist of neonatal Fc receptor (FCGRT) · developed by Immunovant Sciences GmbH
Batoclimab is a fully human monoclonal antibody that binds the neonatal Fc receptor (FcRn) at the IgG binding site, preventing FcRn from rescuing IgG from degradation. It is being studied in myasthenia gravis, Graves' ophthalmopathy, warm autoimmune hemolytic anemia, and chronic inflammatory demyelinating polyneuropathy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05517447 | Phase 3 | Thyroid Eye Disease | Terminated | IMVT |
| NCT05403541 | Phase 3 | Generalized Myasthenia Gravis | Terminated | IMVT |
| NCT05581199 | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy | Terminated | IMVT |
| NCT04253236 | Phase 2 | Warm Autoimmune Hemolytic Anemia | Terminated | IMVT |
| NCT03938545 | Phase 2 | Graves' Ophthalmopathy (GO) | Terminated | IMVT |
| NCT03863080 | Phase 2 | Myasthenia Gravis | Completed | IMVT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Inflammatory Demyelinating PolyneuropathyGeneralized Myasthenia GravisGraves' Ophthalmopathy (GO)Myasthenia GravisThyroid Eye DiseaseWarm Autoimmune Hemolytic Anemia
Updated Oct 18, 2026. Something wrong or missing? Report it on the IMVT page.
See IMVT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMVT catalysts and pipeline →